Skip to main content
Premium Trial:

Request an Annual Quote

Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant


Quark Pharmaceuticals said this week that it has dosed the first patient in a phase I study of its siRNA-based ocular neuroprotectant QPI-1007.

In the study, the drug will be directly delivered to the eyes of legally blind patients and patients with a recent onset of non-arteritic anterior ischemic optic neuropathy, a rare condition that can lead to permanent blindness. Primary endpoints of the trial are safety and tolerability, but Quark will also evaluate whether QPI-1007 has any biological activity in NAION patients.

NAION is the first indication Quark plans to pursue with the drug, but the company ultimately hopes to market QPI-1007 as a treatment for glaucoma.

Previously, the company released preclinical data showing the agent could prevent progressive retinal ganglion cell loss, which is believed to cause the vision loss characteristic of glaucoma, in an increased ocular-pressure rat model of the disease (see RNAi News, 7/30/2009).

Before that, the company released data demonstrating the drug's neuroprotective activity in two different animal models: one of retinal ganglion cell death by optic nerve crush and one of cell death induced by optic nerve axotomy (see RNAi News, 10/2/2008).

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.